B of A Securities Reiterates Underperform on Hims & Hers Health, Maintains $21 Price Target
HIMSMarch 6, 2025
Read more →Citigroup Reiterates Sell on Hims & Hers Health, Maintains $27 Price Target
HIMSMarch 6, 2025
Read more →Texas Northern Court Ruled Against The Outsourcing Facilities Association's Preliminary Injunction Against The FDA; Pharmacies Categorized Under Section 503A Must Cease The Compounding Of Tirzepatide In Bulk Immediately, And Those Under Section 503B Have
HIMSMarch 6, 2025
Read more →Market Whales and Their Recent Bets on HIMS Options
HIMSMarch 6, 2025
Read more →Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
HIMSHims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy.
March 5, 2025
Read more →Hims & Hers Health Unusual Options Activity For February 28
HIMSFebruary 28, 2025
Read more →Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $39
HIMSFebruary 26, 2025
Read more →Hims & Hers Health Analyst Sees Buying Opportunity Following Steep Selloff: 'We See No Reason To Change Our View'
HIMSHims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's what you need to know.
February 25, 2025
Read more →Leerink Partners Maintains Market Perform on Hims & Hers Health, Raises Price Target to $40
HIMSFebruary 25, 2025
Read more →Hims & Hers Health Stock Is Plunging Tuesday: What's Going On?
HIMSHims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to Benzinga Pro. The company reported fourth-quarter earnings of 11 cents per share, in line with analyst estimates.
February 25, 2025
Read more →Piper Sandler Maintains Neutral on Hims & Hers Health, Raises Price Target to $35
HIMSFebruary 25, 2025
Read more →Needham Maintains Buy on Hims & Hers Health, Raises Price Target to $61
HIMSFebruary 25, 2025
Read more →Citigroup Maintains Sell on Hims & Hers Health, Raises Price Target to $27
HIMSFebruary 25, 2025
Read more →Market-Moving News for February 25th
HIMSFebruary 25, 2025
Read more →Hims & Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat
HIMSHims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter.
February 24, 2025
Read more →Hims & Hers Sees FY25 Revenue $2.3B-$2.4B Vs $2.087B Estimate
HIMSFebruary 24, 2025
Read more →Hims & Hers Health Q4 2024 GAAP EPS $0.11, Inline, Sales $481.14M Beat $470.31M Estimate
HIMSFebruary 24, 2025
Read more →Smart Money Is Betting Big In HIMS Options
HIMSFebruary 24, 2025
Read more →What's Going On With Hims & Hers Health Stock Today?
HIMSHims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection shortage.
February 21, 2025
Read more →FDA Says Does Not Intend To Take Action Against Compounders For FD&C Act Violations Depending On Semaglutide Injection Inclusion On Drug Shortage List
HIMSFebruary 21, 2025
Read more →Hims & Hers Acquires U.S.-based Peptide Facility; No Financial Terms Disclosed
HIMSFebruary 21, 2025
Read more →Market Whales and Their Recent Bets on HIMS Options
HIMSInvestors with a lot of money to spend have taken a bearish stance on Hims & Hers Health (NYSE:HIMS). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
February 20, 2025
Read more →B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $21
HIMSFebruary 20, 2025
Read more →Hims & Hers Health Stock Hits All-Time Highs: What's Going On?
HIMSHims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab testing. Positive analyst coverage may also be boosting the stock. Here's what you need to know.
February 19, 2025
Read more →Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $68
HIMSFebruary 19, 2025
Read more →Hims & Hers Acquires An At-Home Lab Testing Facility And Plans To Introduce At-Home Lab testing Through Its Platform
HIMSFebruary 19, 2025
Read more →Assessing Hims & Hers Health: Insights From 7 Financial Analysts
HIMSFebruary 18, 2025
Read more →Morgan Stanley Downgrades Hims & Hers Health to Equal-Weight, Raises Price Target to $60
HIMSFebruary 18, 2025
Read more →Watching Hims & Hers Health; Traders Circulate Popular Retail Trading Newsletter Saying Stock Is Poised For A Major Surge In 2025
HIMSJanuary 10, 2025
Read more →Citigroup Downgrades Hims & Hers Health to Sell, Raises Price Target to $25
HIMSJanuary 10, 2025
Read more →What's Going On With Hims & Hers Health Stock?
HIMSHims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations.
January 9, 2025
Read more →Hims & Hers Health Are Falling Today: What's Going On?
HIMSHims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have impacted the market for GLP-1 receptor agonists. Here's what you need to know.
December 19, 2024
Read more →FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
HIMSDecember 19, 2024
Read more →FDA Issued A New Decision Determining The Tirzepatide Injection Shortage Is Resolved
HIMSDecember 19, 2024
Read more →TD Cowen Reiterates Buy on Hims & Hers Health, Maintains $28 Price Target
HIMSNovember 20, 2024
Read more →Unpacking the Latest Options Trading Trends in Hims & Hers Health
HIMSNovember 18, 2024
Read more →Price Over Earnings Overview: Hims & Hers Health
HIMSNovember 18, 2024
Read more →Peering Into Hims & Hers Health's Recent Short Interest
HIMSNovember 15, 2024
Read more →CORRECTION: B of A Securities Downgrades Hims & Hers Health to Underperform
HIMSNovember 14, 2024
Read more →Assessing Hims & Hers Health: Insights From 7 Financial Analysts
HIMSNovember 6, 2024
Read more →Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $27
HIMSNovember 6, 2024
Read more →Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $21
HIMSNovember 5, 2024
Read more →What's Going On With Hims & Hers Health Stock Tuesday?
HIMSHims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Tuesday after the company reported strong third-quarter results and raised its full-year revenue outlook. Here's what you need to know.
November 5, 2024
Read more →Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $28
HIMSNovember 5, 2024
Read more →Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
HIMSHims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report.
November 4, 2024
Read more →Hims & Hers Sees Q4 2024 Revenue $465M-$470M
HIMSNovember 4, 2024
Read more →Hims & Hers Raises FY24 Revenue Guidance; Sees FY24 Revenue $1.46B-$1.465B Vs $1.396B Estimate
HIMSNovember 4, 2024
Read more →Hims & Hers Health Q3 2024 Adj EPS $0.32 Beats $0.04 Estimate, Sales $401.60M Beat $382.20M Estimate
HIMSNovember 4, 2024
Read more →Decoding Hims & Hers Health's Options Activity: What's the Big Picture?
HIMSNovember 4, 2024
Read more →What's Going On With Hims & Hers Health Stock Monday?
HIMSHims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million, according to estimates from Benzinga Pro.
November 4, 2024
Read more →